NCT00717067 - Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Human Immunodeficiency Virus (HIV) Infection

Interventions

DRUG

Maraviroc

Maraviroc 300 mg (150 mg x 2 tablets) x single dose

DRUG

Maraviroc

Maraviroc 150 mg tablet twice daily x 7 days

DRUG

Ritonavir

Ritonavir 100 mg capsule twice daily x 7 days

DRUG

Saquinavir

Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days

DRUG

Maraviroc

Maraviroc 150 mg tablet once daily x 7 days

DRUG

Ritonavir

Ritonavir 100 mg capsule twice daily x 7 days

DRUG

Saquinavir

Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days

DRUG

Maraviroc

Maraviroc 150 mg tablet once every 48 hours x 7 days

DRUG

Ritonavir

Ritonavir 100 mg capsule twice daily x 7 days

DRUG

Saquinavir

Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days

DRUG

Maraviroc

Maraviroc 300 mg (150 mg x 2 tablets) x single dose

DRUG

Maraviroc

Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis

DRUG

Maraviroc

Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis

Trial Locations (2)

10117

Pfizer Investigational Site, Berlin

81241

Pfizer Investigational Site, München